Skip to content
Screener

Amylyx Pharmaceuticals, Inc. AMLX Total Liabilities & Equity

Total Liabilities & Equity at other companies

MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$452.7M+84.1%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$608.24M-29.8%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$1.4B+2.9%
VAN
Vivani MedicalVANI
$42.35M+19.5%
uniQure logo
uniQureQURE
$985.1M+68.4%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$244.66M+9.2%

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$45.7M-6.6%
Net income-$43.4M-4.8%
EPS (diluted)-$0.39+15.2%

Balance sheet

See full
Cash & equivalents$49.3M-15.1%
Total debt$5.3M-11.9%
Total equity$239.2M+42.5%
Total assets$264.6M+36.0%

Cash flow

See full
Operating cash flow-$31.4M-24.5%
CapEx$86.0K+330%
Free cash flow-$28.0M+52.6%

Valuation

See full
Market cap$2.7B+269%
Enterprise value$2.65B+291%

Profitability

See full
Gross margin100%+6.9pp
Operating margin-47,349.8%-47,409pp
Net margin-45,096.2%-45,152pp
FCF margin-39,826.7%-39,847pp

Returns & leverage

See full
Return on equity-74.7%-9.5pp
Debt / equity0.0×
Current ratio12.1×+3.4×

Where this comes from

Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:04 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336682
Line itemJune 30, 2026December 31, 2025
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value; 300,000,000 shares authorized; 111,368,283 and 109,884,502 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively1111
Additional paid-in capital1,075,2711,056,271
Accumulated deficit(836,134)(751,427)
Accumulated other comprehensive income19404
Total stockholders’ equity239,167305,259
Total liabilities and stockholders’ equity$264,564$332,645

Item 1. Financial Statements.

FAQ

What is Amylyx Pharmaceuticals, Inc.'s total liabilities & equity?
Amylyx Pharmaceuticals, Inc. (AMLX) reported total liabilities & equity of $264.56M in Q2 2026.
How has Amylyx Pharmaceuticals, Inc.'s total liabilities & equity changed year-over-year?
Amylyx Pharmaceuticals, Inc.'s total liabilities & equity increased by 36.0% year-over-year, from $194.6M to $264.56M.
What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s total liabilities & equity?
Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s total liabilities & equity has grown at a 33.2% compound annual growth rate (CAGR), from $105.61M to $332.65M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Amylyx Pharmaceuticals, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude